𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

✍ Scribed by Stilgenbauer, S.; Zenz, T.; Winkler, D.; Buhler, A.; Schlenk, R. F.; Groner, S.; Busch, R.; Hensel, M.; Duhrsen, U.; Finke, J.; Dreger, P.; Jager, U.; Lengfelder, E.; Hohloch, K.; Soling, U.; Schlag, R.; Kneba, M.; Hallek, M.; Dohner, H.

Book ID
118269173
Publisher
American Society of Clinical Oncology
Year
2009
Tongue
English
Weight
170 KB
Volume
27
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Subcutaneous Alemtuzumab in Fludarabine-
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
✍ Stilgenbauer, S.; Zenz, T.; Winkler, D.; Buhler, A.; Schlenk, R. F.; Groner, S.; πŸ“‚ Article πŸ“… 2009 πŸ› American Society of Clinical Oncology 🌐 English βš– 170 KB

## Purpose The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical and biologic markers were evaluated for their impacts on outcome. ## Patients and Methods One hundred nine patients